CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
about
Biomaterial-enabled delivery of SDF-1α at the ventral side of breast cancer cells reveals a crosstalk between cell receptors to promote the invasive phenotype.Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes.Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains.CXCL12-CXCR4 axis in feline mammary carcinoma.Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis.Identification of Differentially Expressed Genes between Original Breast Cancer and Xenograft Using Machine Learning Algorithms.miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers.Clinicopathologic Significance of CXCL12 and CXCR4 Expressions in Patients with Colorectal Cancer.The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment
P2860
Q38747909-1865F9CD-99D5-4458-B8D9-96ACB420845FQ47146848-D7616AA0-558A-43F0-99DA-9327AA54CF59Q49874416-A4740ED5-FD3D-4DE2-AEB5-08B1D7EF1529Q49894726-E7E18AA7-AE6A-4E7D-8E5E-21C33AD15F61Q50100841-1151339B-35A5-41DF-BE07-7BDBBEDBB2A4Q52657721-61D092B3-5E49-4A02-9BC8-2FED54C3726BQ54975654-BB44196F-CC9B-4E28-A150-3517AC492FC6Q55019874-4B085D0E-ADCF-4B35-8763-734993D70916Q57492022-A0865F87-323E-4E38-A10C-6CFD9C650562
P2860
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
@en
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
@nl
type
label
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
@en
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
@nl
prefLabel
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
@en
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
@nl
P2093
P2860
P50
P356
P1433
P1476
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
@en
P2093
A Vincent-Salomon
P2860
P2888
P304
P356
10.1038/ONC.2016.284
P407
P577
2016-09-26T00:00:00Z
P6179
1050812094